摘要
目的 :探讨霉菌素阴道泡腾片、硝夫太尔片联合重组人干扰素α-2b栓治疗假丝酵母菌性阴道炎(CAV)的疗效及安全性分析。方法:选取2013年12月-2016年3月我院收治的CAV患者148例,按随机数字表法分为对照组和观察组,各74例。对照组给予克霉唑栓(0.15 g,qd)+口服制霉菌素片(50万U,tid)进行治疗,观察组给予制霉菌素阴道泡腾片(10万U,qod)+口服硝夫太尔片(0.2 g,tid)+重组人干扰素α-2b栓(50万IU,qod)进行治疗。观察并比较两组治疗后临床疗效。结果 :治疗后,两组尿常规异常率、丙氨酸氨基转移酶异常率及血肌酐异常率较治疗前下降,且观察组尿常规异常率、丙氨酸氨基转移酶异常率及血肌酐异常率均低于对照组(P<0.05)。治疗后,观察组外阴红肿、外阴瘙痒疼痛、阴道分泌物及黏膜充血评分均低于对照组疗后(P<0.05)。两组治疗后,观察组外阴红肿、外阴瘙痒痒疼痛、阴道分泌物及黏膜充血评分均低于对照组(P<0.05)。两组不良反应发生率比较无统计学差异(P>0.05)。结论:霉菌素阴道泡腾片、硝夫太尔片联合重组人干扰素α-2b栓治疗CAV疗效显著,可有效改善患者临床症状,提高患者生活质量,且安全性高。
Objective:To analyze the efficacy and safety of nystatin vaginal effervescent tablets and nifuratel tablet combined with recombinant human interferon alpha-2 b suppository in the treatment of candida albicans vaginitis(CAV). Methods:148 CAV patients admitted from December 2013 to March 2016 in People's Hospital of Yiyang Country were randomly divided into the control group and the observation group, with 74 cases in each group. Patients in the control group were treated with clotrimazole suppositories(0.15 g) and nystatin tablets(0.5 million U, tid), while patients in the observation group were treated with nystatin vaginal effervescent tablets(0.1 million U, qod) and nifuratel tablet(0.2 g, tid) combined with recombinant human interferon alpha-2 b suppository(0.5 million IU, qod). The clinical therapeutic efficacy after treatment of the two groups was observed and compared. Results:Abnormal rates of the routine urine test, alanine aminotransferase and serum creatinine of patients in the two groups after treatment decreased compared with those before treatment, and the abnormal rates of the routine urine test, alanine aminotransferase and serum creatinine of patients in the observation group were lower than those in control group after treatment(P<0.05). Genital swelling and itching, vaginal secretion and mucosa hyperemia scores of patients in the observation group after treatment decreased compared with those before treatment, and the scores after treatment in the observation group were lower than those in control group(P<0.05). There was no significant statistical difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion:Nystatin vaginal effervescent tablets and nifuratel tablet combined with recombinant human interferon alpha-2 b suppository showed superior efficacy in the treatment of CAV, which could effectively improve the clinical symptoms of patients and improve the quality of life of patients with high safety.
出处
《中国执业药师》
CAS
2018年第3期44-47,共4页
China Licensed Pharmacist
关键词
霉菌素阴道泡腾片
硝夫太尔片
假丝酵母菌
阴道炎
Nystatin Vaginal Effervescent Tablets
Nifuratel Tablet
Candida Albicans
Vaginitis
